

Title Drug Treatments

Reference Number: RDF1735-23

Date of Response: 21/08/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

	Trust totals
Ipilimumab (monotherapy)	*<5
Nivolumab (monotherapy)	*<5
Nivolumab AND Ipilimumab (combination)	*<5
Pembrolizumab	*<5
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	6
Other active systemic anti-cancer therapy	*<5

[] Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?

	Trust totals
Nivolumab (monotherapy)	*<5
Nivolumab + Ipilimumab	0
Nivolumab + Cabozantinib	0
Avelumab + Axitinib	*<5

[] Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

	Trust totals
Nivolumab monotherapy or in combination with Ipilimumab	*<5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	0
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	*<5

[] Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

*<5 - Section 40 (2)

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases, ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.